Last reviewed · How we verify
Ammonul
At a glance
| Generic name | Ammonul |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy (PHASE2)
- A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ammonul CI brief — competitive landscape report
- Ammonul updates RSS · CI watch RSS
- Amgen portfolio CI